Neurological involvement in systemic lupus erythematosus

Current Opinion in Neurology

Volumn 11, Issue 3, 1998, Pages 247-251

  McLean, Brendan N ^a  

^a ROYAL CORNWALL HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BETA2 GLYCOPROTEIN 1; CYCLOPHOSPHAMIDE; PHOSPHOLIPID ANTIBODY; PHOSPHOLIPID BINDING PROTEIN; PROSTAGLANDIN E2; STEROID; THROMBOXANE SYNTHASE INHIBITOR;

COGNITIVE DEFECT; HUMAN; IMAGING; MENTAL DISEASE; NEUROLOGIC DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; RETROVIRUS; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS;

ANIMALS; ANTIBODIES; ANTIBODIES, ANTIPHOSPHOLIPID; COGNITION DISORDERS; DIAGNOSTIC IMAGING; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; NERVOUS SYSTEM DISEASES; NEURONS; PROTOZOAN PROTEINS; RIBOSOMAL PROTEINS;

EID: 0031810168     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-199806000-00010     Document Type: Review

References (27)

1. West SG. Neuropsychiatric lupus. Rheum Dis Clin North Am 1994; 20:129-158.
2. West SG. Lupus and the nervous system. Curr Opin Rheumatol 1996; •• 8:408-414. This is thorough and well referenced review of recent articles on the subject, concentrating on neuropsychiatric manifestations and diagnostic tests.
3. Denburg SD, Denburg JA, Carbotle RM, Fisk JD, Hanley JG. Cognitive deficits in systemic lupus erythematosus. Rheum Dis Clin North Am 1993; 19:815-831.
4. Urowitz MB, Gladman BD, Slaim D, Glanz B, Gough J, Pauzner R, et al. Neurocognitive dysfunction in patients with inactive systemic lupus erythematosus. Arthritis Rheum 1995; 39 (Suppl):302.
5. Waterloo K, Omdal R, Mellgren SI, Husby G. Neuropsychological functions • in systemic lupus erythematosus: a comparison with chronic whiplash patients. Eur J Neurol 1997; 4:171-177. Thirty-six patients with SLE underwent a battery of neuropsychological tests, and 31 chronic whiplash patients were used as control individuals. Significant cognitive impairment was found, independent of any depressive component, indicating CNS involvement.
6. Matsumoto R, Nakano I, Shiga J. Systemic lupus erythematosus with multiple perivascular spongy changes in the cerebral deep structures, midbrain and cerebellar white matter. A case report. J Neurol Sci 1997; 145:147-153.
7. Nakano I, Mannen T, Mizutani T, Yokohari R. Peripheral white matter lesions of the spinal cord with changes in small arachnoid arteries in systemic lupus erythematosus. Clin Neuropathol 1989; 8:102-108.
8. Takayanagui OM, Moura LS, Petean FC, Biscaro TA, Covas DT, Osame M. Human T-lymphotorpic virus type-I-associated myelopathy/tropical spastic paraparesis and systemic lupus erythematosus. Neurol 1997; 48:1469-1470.
9. Bailer RT, Lazo A, Harisdangkul V. Lack of evidence of human T cell lymphotrophic virus type I or II infection in patients with systemic lupus erythematosus or rheumatoid arthritis. J Rheumatol 1994; 21:2217-2224.
10. Scott TF, Goust JM, Strange CB, Brillman J. SLE, thrombocytopenia and HTLV-1. J Rheumatol 1990; 17:1565-1566.
11. Rasmussen HB, Clausen J. Possible involvement of endogenous retroviruses in the development of autoimmune disorders, especially multiple sclerosis. Acta Neurol Scand 1997; 95(Suppl 169):32-37.
12. Cabral AR, Alarcon-Segovia D. Autoantibodies in systemic lupus • erythematosus. Curr Opin Rheumatol 1997; 9:387-392. This is good review of immunological abnormalities found in SLE, including the role of antiphospholipid antibodies and antiribosomal P protein antibodies.
13. Alarton-Segovia D, Cabral AR. Autoantibodies in Systemic lupus • Erythematosus. Curr Opin Rheumatol 1996; 8:403-407. This review converts the same ground as that by [11].
14. Watanabe T, Sato T, Uchiumi T, Arakawa M. Neuropsychiatric manifestations in patients with systemic lupus erythematosus: diagnostic and predictive value of longitudinal examination of anti-ribosomal P antibody. Lupus 1996; 5:178-183.
15. Agius MA, Chan JW, Chung S, Lee EK. Role of antiribosomal P protein • antibodies in the diagnosis of lupus isolated to the central nervous system. Arch Neuol 1997; 54:862-864. A case report is presented of a patient with only neurological manifestations of SLE diagnosed on the basis of serum antiribosomal P protein antibodies, who responded to steroid treatment with clinical recovery and antibody titre reduction.
16. Hughes GRV. Thrombosis, abortion, cerebral disease and the lupus anticoagulant. BMJ 1983; 287:1088-1089.
17. Tincani A, Spatola L, Prati E, Allegri F, Ferremi P, Cattaneo R, et al. The anti-B2-glycoprotein I activity in human anti-phospholipid syndrome sera is due to monoreactive low-affinity autoantibodies directed to epitopes located on native B2-glycoprotein I and preserved during species' evolution. J Immunol 1996; 157:5732-5738.
18. Ziporen L, Schoenfeld Y, Levy Y, Korezyn AD. Neurological dysfunction and hyperactive behaviour associated with antiphospholipid antibodies. A mouse model. J Clin Invest 1997; 100:613-619.
19. Cabral AR, Amigo MC, Cabiedes J, Alarcon-Segovia D. The antiphospho•lipid/cofactor syndromes: a primary variant with antibodies to B2-glycoprotein I but no antibodies detectable in standard antiphospholipid assays. Am J Med 1996; 101:472-481. This is the first description of patients with an antiphospholipid syndrome, including thrombotic events, having antibodies only to β2-glycoprotein-1 and not antiphospholipid antibodies.
20. Tishler M, Alosachie I, Chapman Y, Koreyn A, Lorber M, Mevorach D. et al. Anti-neuronal antibodies in antiphospholipid syndrome with central nervous system involvement: the difference from systemic lupus erythematosus. Lupus 1995; 4:145-147.
21. McLean BN, Miller D, Thompson EJ. Oligoclonal banding of IgG in CSF, blood brain barrier function and MRI findings in patients with sarcoidosis, systemic lupus erythematosus, and Behcets disease involving the nervous system. J Neurol Neurosurg Psychiatry 1995; 58:518-554.
22. Fainardi E, Vaghi L, Govoni M, Tola MR, Trotta F, Paolino E. Intrathecal IgG production and blood-CSF barrier dysfunction in Cerebral lupus. J Immunol 5315:S32.
23. Sailer M, Burchert W, Ehrenheim C, Smio HGOM, Haas J, Wildhagen R, • et al. Positron emission tomography and magnetic resonance imaging for cerebral involvement in patients with systemic lupus erythematosus. J Neurol 1997; 244:186-193. This interesting paper compared PET and MRI in patients with neuropsychiatric SLE, finding no abnormalities in PET with any neurological involvement, and no MRI changes in cognitively impaired patients, but these were present in those with other neuropsychiatric manifestations.
24. Huang JC, Yeh KW, You DL, Hsieh KH. Serial single photon emission computed tomography imaging in patients with cerebral lupus during acute exacerbation and after treatment. Paediatr Neurol 1997; 17:44-48.
25. Ramos PC, Mendez MS, Ames PRJ, Khamashta MA, Hughes GRV. Pulse cyclophosphamide in the treatment of neuropsychiatric systemic lupus erythematosis. Clin Exp Rheumatol 1996; 14:295-299.
26. Strand V. Approaches to the management of systemic lupus erythematosis. •• Curr Opin Rheumatol 1997; 9:410-420. This is a very good overview of current and experimental treatment approaches to SLE in general.
27. Yoshikawa Y, Mizutani H, Shimizu M. Systemic lupus erythematosus with ischaemic peripheral neuropathy and lupus anticoagulant: response to intravenous prostaglandin E1. Cutis 1996; 58:393-396.